Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
Matsuda C, Munemoto Y, Mishima H, Nagata N, Oshiro M, Kataoka M, Sakamoto J, Aoyama T, Morita S, Kono T. Matsuda C, et al. Among authors: nagata n. Cancer Chemother Pharmacol. 2015 Jul;76(1):97-103. doi: 10.1007/s00280-015-2767-y. Epub 2015 May 17. Cancer Chemother Pharmacol. 2015. PMID: 25983022 Free PMC article. Clinical Trial.
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, Sakamoto J, Mishima H. Kono T, et al. Among authors: nagata n. Cancer Chemother Pharmacol. 2013 Dec;72(6):1283-90. doi: 10.1007/s00280-013-2306-7. Cancer Chemother Pharmacol. 2013. PMID: 24121454 Free PMC article. Clinical Trial.
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H, Maeda H, Hasegawa J, Takahashi T, Hazama S, Fukunaga M, Kono E, Kotaka M, Sakamoto J, Nagata N, Oba K, Mishima H. Soda H, et al. Among authors: nagata n. BMC Cancer. 2015 Oct 14;15:695. doi: 10.1186/s12885-015-1685-z. BMC Cancer. 2015. PMID: 26467662 Free PMC article. Clinical Trial.
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
Matsuda C, Honda M, Tanaka C, Fukunaga M, Ishibashi K, Munemoto Y, Hata T, Bando H, Oshiro M, Kobayashi M, Tokunaga Y, Fujii A, Nagata N, Oba K, Mishima H. Matsuda C, et al. Among authors: nagata n. Int J Clin Oncol. 2016 Jun;21(3):566-72. doi: 10.1007/s10147-015-0911-7. Epub 2015 Oct 16. Int J Clin Oncol. 2016. PMID: 26475356 Clinical Trial.
Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein: a multicenter randomized phase II study (APOLLO).
Hata T, Honda M, Kobayashi M, Toyokawa A, Tsuda M, Tokunaga Y, Takase K, Miyake M, Morita S, Nagata N, Sakamoto J, Gosho M, Mishima H. Hata T, et al. Among authors: nagata n. Cancer Chemother Pharmacol. 2015 Dec;76(6):1209-15. doi: 10.1007/s00280-015-2888-3. Epub 2015 Nov 11. Cancer Chemother Pharmacol. 2015. PMID: 26560483 Clinical Trial.
A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial.
Munemoto Y, Kanda M, Oba K, Kim HM, Takemoto H, Denda T, Nagata N, Takano N, Fukunaga M, Kataoka M, Tokunaga Y, Sakamoto J, Mishima H. Munemoto Y, et al. Among authors: nagata n. Cancer Chemother Pharmacol. 2018 May;81(5):829-838. doi: 10.1007/s00280-018-3556-1. Epub 2018 Mar 5. Cancer Chemother Pharmacol. 2018. PMID: 29508026 Clinical Trial.
The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C).
Nishikawa K, Aoyama T, Oba MS, Yoshikawa T, Matsuda C, Munemoto Y, Takiguchi N, Tanabe K, Nagata N, Imano M, Oshiro M, Fukushima R, Kataoka M, Morita S, Tsuburaya A, Mishima H, Kono T, Sakamoto J. Nishikawa K, et al. Among authors: nagata n. J Cancer. 2018 Apr 19;9(10):1725-1730. doi: 10.7150/jca.24733. eCollection 2018. J Cancer. 2018. PMID: 29805697 Free PMC article.
Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study).
Ishibashi K, Aoyama T, Kotaka M, Satake H, Tsuji Y, Kataoka M, Nakamura M, Nagata N, Sakamoto J, Oba K, Mishima H. Ishibashi K, et al. Among authors: nagata n. Cancer Chemother Pharmacol. 2021 May;87(5):665-672. doi: 10.1007/s00280-021-04232-2. Epub 2021 Feb 8. Cancer Chemother Pharmacol. 2021. PMID: 33555359 Free PMC article. Clinical Trial.
Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.
Watanabe J, Maeda H, Nagasaka T, Yokota M, Hirata K, Akazawa N, Kagawa Y, Yamada T, Shiozawa M, Ando T, Kato T, Mishima H, Sakamoto J, Oba K, Nagata N. Watanabe J, et al. Among authors: nagata n. Int J Cancer. 2022 Dec 15;151(12):2172-2181. doi: 10.1002/ijc.34184. Epub 2022 Jul 5. Int J Cancer. 2022. PMID: 35723084 Clinical Trial.
1,376 results